Aviceda Therapeutics
Industry
- Pharmaceuticals
- Biotechnology
See more in Biomedtracker
Latest on Aviceda Therapeutics
Scrip
• By Mandy Jackson
The week before the annual J.P. Morgan Healthcare Conference always brings a flurry of new venture capital financings and the tradition continued in 2025, including Aviceda Therapeutics with a $207.5m
Scrip
• By Alaric DeArment
In the more than six years since the US Food and Drug Administration approved Novartis AG ’s Kymriah (tisagenlecleucel) and Kite Pharma’s – now part of Gilead Sciences, Inc. – Yescarta (axicabtagen